Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update
JOURNAL OF CLINICAL ONCOLOGY（2022）
关键词
immune checkpoint inhibitor,estrogen receptor,pembrolizumab,gper,refractory solid malignancies,first-in-class,protein-coupled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要